The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The proliferative diabetic retinopathy (PDR) market has experienced rapid growth in recent years, and this trajectory is set to continue. The market size is projected to increase from $2.16 billion in 2023 to $2.42 billion in 2024, showcasing a remarkable Compound Annual Growth Rate (CAGR) of 11.7%. Looking ahead, the market is anticipated to see rapid growth, reaching $3.62 billion in 2028 with a CAGR of 10.6%. This evolution is underpinned by various factors shaping both historical and forecasted periods.

• Historical Drivers:
  • Growing prevalence of diabetes.
  • Changes in lifestyle and unhealthy food habits.
  • Government initiatives.
  • Rising cases of diabetes-related vision loss.
• Forecasted Catalysts:
  • Aging global population.
  • Public awareness and education about diabetes.
  • Increased research and development funding.
  • Rising demand for combination therapies.
• Emerging Trends:
  • Advancements in diagnostic technologies.
  • Innovations in treatment options.
  • Utilization of artificial intelligence (AI) for early diagnosis.
  • Gene therapy advancements.
  • Advanced retinal imaging.

Diabetes Surge: A Driving Force

The escalating prevalence of diabetes is a key driver propelling the growth of the proliferative diabetic retinopathy (PDR) market. Diabetes, characterized by elevated blood glucose levels, is a significant contributor to PDR. The condition, if untreated, can lead to severe vision impairment or even blindness. The International Diabetes Federation reports staggering numbers, with 537 million adults suffering from diabetes globally in 2021, expected to reach 783 million by 2045. This surge in diabetes cases directly fuels the expansion of the PDR market.

• Market Players:
  • Leading companies include Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., and others.

View More On The Proliferative Diabetic Retinopathy (PDR) Market Report 2023 – https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Innovative Therapies Transform the Landscape

Major companies in the proliferative diabetic retinopathy market are at the forefront of introducing groundbreaking therapies to revolutionize treatment approaches. For example, in June 2022, Biogen and Samsung Bioepis launched Byooviz, the first ophthalmology biosimilar in the US, targeting diabetic macular edema, proliferative diabetic retinopathy, wet age-related macular degeneration, and choroidal neovascularization.

• Byooviz Highlights:
  • Ranibizumab-nuna biosimilar.
  • Addresses diabetic macular edema and proliferative diabetic retinopathy.
  • Represents a significant advancement in treatment options.

Strategic Collaborations for Gene Therapy Advancements

In a strategic move, AbbVie, a US-based pharmaceutical company, partnered with REGENXBIO Inc. in September 2021, aiming to advance RGX-314, a gene therapy for proliferative diabetic retinopathy (PDR) and wet age-related macular degeneration (wet AMD).

• Collaboration Highlights:
  • Focus on developing and marketing RGX-314 gene therapy.
  • Targets wet AMD, diabetic retinopathy, and other retinal diseases.
  • Utilizes subretinal and suprachoroidal administration for different clinical trials.

Market Dynamics and Segmentation Insights

Understanding the PDR market requires insight into its dynamics and segmentation.

• Market Segmentation:
  • Treatment types include Anti-VEGF Therapy, Intraocular Steroids, Laser Surgery, and Vitrectomy.
  • Modes of administration encompass Injectables, Oral, and other modes.
  • Applications extend to Hospitals, Clinics, and other sectors.
• Regional Dominance:
  • North America emerged as the largest region in the proliferative diabetic retinopathy market in 2023.
  • Asia Pacific is poised to be the fastest-growing region in the forecast period.

Navigating a Clearer Future

As the PDR market continues to evolve, driven by diabetes prevalence, innovation, and strategic collaborations, it is on a trajectory towards providing advanced and effective treatments. Advancements in diagnostic technologies, gene therapy, and the application of artificial intelligence are reshaping the landscape, ensuring a clearer future for those affected by proliferative diabetic retinopathy.

Request A Sample Of The Global Proliferative Diabetic Retinopathy (PDR) Market Report 2023:

https://www.thebusinessresearchcompany.com/sample_request?id=12911&type=smp

The Proliferative Diabetic Retinopathy (PDR) Global Market Report 2023  provides a comprehensive overview on the proliferative diabetic retinopathy (PDR) market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the proliferative diabetic retinopathy (PDR) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –

Digital Diabetes Management Global Market Report 2023

Diabetes Care Devices Global Market Report 2023

Artificial Intelligence In Diabetes Management Global Market Report 2023

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model